Current Trends in Osteoporosis Diagnostics: An Opportunity for Quantitative Ultrasound and Biomarkers

Marnie M Saunders*1, Sharon L Truesdell1, Estee L George1, James H Holda2 and Christopher Van Vranken1

1Department of Biomedical Engineering, The University of Akron, USA
2Department of Biology, The University of Akron, USA

*Corresponding author: Marnie M Saunders, Department of Biomedical Engineering, The University of Akron, Akron, OH 44325-0302, USA

ARTICLE INFO

Received: November 02, 2019
Published: November 19, 2019


Keywords: Osteoporosis; Diagnostics; Ultrasonics; Microfluidics; Point-of-Care

ABSTRACT

Osteoporosis, characterized by diminished bone strength and increased susceptibility to fragility fracture, affects hundreds of millions throughout the world. Given the aging population, this number is only expected to grow. Currently dual x-ray absorptiometry (DXA) is the best tool for diagnosing osteoporosis; however, 75% of the affected global population remains undiagnosed and untreated. DXA scans give bone mineral density values that are indicative of bone strength. However, other risk factors must also be considered to accurately assess fracture probability. The World Health Organization released the fracture risk assessment algorithm (FRAX®) to accompany DXA scans and predict 10-year fracture risk, but the online tool better predicts those who will not suffer fragility fractures. Quantitative ultrasound can be used to assess bone microarchitecture and other properties leading to a better understanding of bone strength. Microfluidics can be used to measure bone turnover markers from small sample volumes. When coupled with point-of-care systems, these technologies can reach those in need. This review discusses these tools in advancing osteoporosis diagnostics and its subsequent treatment.


Introduction

Osteoporosis is a pathological decrease in bone mineral density (BMD) that increases risk of fragility fracture [1]. Osteoporosis affects 200 million people across the globe [2] and is undiagnosed and undertreated [3]. The onset of osteoporosis is influenced by lifestyle choices, such as diet, exercise and tobacco use [4-6], as well as additional risk factors, such as age and gender [1,6]. Postmenopausal women are particularly susceptible to the disorder and are generally advised to undergo routine examinations for bone health assessment. Given that emphasis is placed on diagnosing high-risk women, men are often overlooked [7]. The onset of
osteoporosis may be predicted by peak bone mass (PBM), which is attained in the third decade of life [8,9]. Pediatricians suggest PBM accumulation, which is affected by several factors during growth, may be a powerful defense against development of osteoporosis later in life [10]. While preventative measures help reduce the risk of osteoporosis and associated fracture, prevention is not always an option. As such, diagnosis and treatment are needed to reduce morbidity and mortality and to increase quality of life.

Osteoporosis reduces bone mass, while bone cells work simultaneously to maintain a normal ratio of mineralized to non-mineralized matrix [1]. BMD is decreased when bone deviates from homeostasis and the rate of bone resorption exceeds the rate of bone formation. Osteoporosis is classified as either primary or secondary, where the former is senile or idiopathic [11] and the latter is due to drug intake, unloading or another disorder [12]. Bone mass is a significant determinant of fracture occurrence; thus, as BMD decreases, the risk of fragility fracture increases [11]. Osteoporosis often goes undetected until the onset of a fracture, and even then, diagnosis and treatment are not guaranteed [13,14].

One study involving over 2,000 women aged 50 years and older demonstrated that fragility fractures occurred in 81% of those who suffered a fracture. Moreover, the study reported that 79% of those individuals did not receive appropriate follow-up care or treatment for osteoporosis six to eight months following fracture [15]. The current gold standard for diagnosis of osteoporosis is by means of dual-energy X-ray absorptiometry (DXA) scanning [16].

The scan applies two distinct X-ray beams at the femoral head or lumbar region of the spine to obtain values for bone mineral content (BMC) and bone area (BA). From here, areal BMD can be calculated [17]. DXA requires specialized facilities, expensive laboratory equipment and highly trained medical personnel to operate and to calibrate the scanner [18,19]. Presently no technology can achieve the same clinical standard of osteoporotic diagnosis as DXA. However, it is estimated that 75% of the affected global population remains untreated [3]. As such, there is a significant need to develop more cost-effective and portable alternatives to DXA.

The purpose of this review is to assess current bone health diagnostics and existing trends in the field. We discuss the globally accepted standards for measuring bone health-DXA and FRAX®-as established by the World Health Organization (WHO). Additionally, we explore recent advancements in diagnosis of osteoporosis by means of ultrasound, microfluidic technologies, bone turnover markers (BTMs), and point-of-care (POC) systems. We conclude that, with further technological and research advancements, the future of bone health diagnostics will be based on quantitative microfluidics for the analysis of BTMs and quantitative ultrasound for the assessment of bone fragility.

**Current Bone Health Diagnostics**

**Dual-Energy X-Ray Absorptiometry**

DXA scans use two X-ray beams of distinct energies: one to detect bone and the other to detect soft tissue. The scan measures BMC in grams and BA in square cm; these measurements are usually taken at the femoral head or the lumbar region of the spine. Areal BMD—determined by dividing BMC by BA—gives a patient's T- and Z-score. The T- and Z-scores are interpreted by calculating standard deviations from the mean BMDs of young healthy adults of the same sex and healthy adults of the same age, respectively [17]. A T-score of -1 or greater indicates normal BMD, a score between -1 and -2.5 indicates osteopenia, and a score of less than -2.5 indicates osteoporosis [1]. Osteoporosis is considered severe when risk of fragility fracture is also present [20]. When the scanners are maintained appropriately and operated by highly trained personnel, quality DXA reports can be generated. However, numerous studies have revealed that calibration, operation and maintenance of the equipment as well as interpretation of scans are highly variable [18,21].

In response the International Society for Clinical Densitometry (ISCD) released a set of guidelines titled “Best Practices for Dual-Energy X-ray Absorptiometry Measurement and Reporting.” The guidelines pertain to scan acquisition and analysis, as well as interpretation and reporting. The ISCD made numerous recommendations, including:

1) Spine phantom BMD measurements should be taken once a week to maintain a tolerance of ±1.5%.
2) At least one DXA technologist and one interpreter should have valid certifications in bone densitometry.
3) Each technologist should have completed an *in vivo* precision assessment.
4) The facility least significant change should be determined.

DXA scans require technologists, clinicians, interpreters and supervisors and results can vary greatly if these personnel are not proficient in recognizing confounding artifacts and other sources of error [18,19]. Use of DXA has certain disadvantages. Due to the size and complexity of the equipment, specialized facilities are required to house the scanners. Moreover, skilled medical personnel are necessary to operate and calibrate the device and interpret the results [18,19]. And, due to high demand, patients may have to wait long periods of time before scanners become available [22]. In summary, the resources required for operation of DXA scanners and their lack of portability render them inaccessible to much of the world.

**Trabecular Bone Score and Vertebral Fracture Assessment**

Several technologies exist that can be used alongside DXA to better identify persons at risk of fracture. Central DXA scans, more specifically those of the lumbar spine, can be further evaluated to determine a trabecular bone score (TBS). This value is computer software generated and provides an evaluation of overall bone microarchitecture. The TBS software estimates a 3D structure using...
the pixel differences from the 2D projection images. For postmeno-
pausal women, a TBS above 1.350 indicates healthy microarchitec-
ture, while a TBS below 1.200 indicates degraded microarchitec-
ture. A TBS between these two values indicates microarchitecture
that is partially degraded. No ranges for men have yet been estab-
lished [23]. Several studies have demonstrated the utility of TBS in
identifying patients at risk of vertebral fracture [23-25].

Another technology that utilizes central DXA is the vertebral
fracture assessment (VFA). This lateral scan of the spine can be
taken at the same time as DXA to examine the vertebrae for
presence of fracture. The ability to run VFA in parallel reduces
cost and radiation exposure; however, it is necessary to be able to
identify additional patient risk factors. It is for this reason the WHO
developed a fracture risk assessment algorithm (FRAX\textsuperscript{®}) that incorporates femoral neck DXA
BMD measurements and determines the 10-year probability of a
patient 40 years or older suffering a fracture [28]. FRAX\textsuperscript{®}, available
online, is nation-specific, as demographics alter fracture risk [29].
DXA measurements may be entered into the assessment tool,
though they are not necessary for the calculation. To determine
individual fracture risk FRAX\textsuperscript{®} uses ten patient-specific factors,
including age, sex, weight, height, previous fracture occurrence,
tobacco use and femoral neck BMD (as determined by DXA) [29,30].

Studies demonstrate that FRAX\textsuperscript{®} results in high specificity but
low sensitivity in the diagnosis of osteoporosis [22,31]. In other
words, the assessment tool adequately identifies patients with-
out the disease but fails to identify a portion of patients with the
disease. Therefore FRAX\textsuperscript{®} is best used in conjunction with DXA to
identify patients at risk. While this tool helps persons not at risk to
avoid unnecessary and expensive tests, it may also provide a false
sense of security to those in danger of suffering fragile fractures.
Additionally, the tool may help lower screening costs, but it does
not adequately identify those who require diagnosis and treatment.
A similar tool is the Fracture Risk Calculator developed by Garvan
Institute. The online tool incorporates four clinical risk factors
and BMD for patients 50 years or older. These factors include age,
sex, number of falls in last 12 months and fractures since the age
of 50 [32]. While FRAX\textsuperscript{®} was developed from data from 20 popu-
lation-based cohorts throughout the world, the Garvan calculator
was developed from the Dubbo Osteoporosis Epidemiology Study
[32-34].

One New Zealand study evaluated both the FRAX\textsuperscript{®} and Garvan
calculators by conducting a 5-year randomized, placebo-controlled
study including over 1,400 postmenopausal women. BMD of the
femoral neck was determined by DXA for each participant and
they were asked to report fractures at 6-month intervals. The study
determined that neither calculator had better predictive capabilities
than models that incorporate only age and BMD. In addition, the discriminate ability of either tool was only moderate.
The FRAX\textsuperscript{®} calculator with BMD underestimated osteoporotic and
hip fractures. When used without BMD, the tool underestimated
osteoporotic fractures but overestimated hip fractures. The Garvan
tool was well suited for osteoporotic fractures but underestimated
hip fractures [32]. The inaccuracies of these tools put physicians
and patients at risk of incorrect treatment.

Fracture Risk Assessment Algorithm and Garvan
Fracture Risk Calculator

Studies show that a large portion of individuals who suffer
fragility fractures have BMD T-scores above the osteoporotic range
and sometimes even in the healthy range [1]. This demonstrates that
a low BMD is not the only fracture risk factor. As fragility fractures are
the primary cause of morbidity and mortality among osteoporotic
patients, it is imperative to be able to identify additional patient
risk factors. It is for this reason the WHO developed a fracture risk
assessment algorithm (FRAX\textsuperscript{®}) that incorporates femoral neck DXA
BMD measurements and determines the 10-year probability of a
patient 40 years or older suffering a fracture [28]. FRAX\textsuperscript{®}, available
online, is nation-specific, as demographics alter fracture risk [29].
DXA measurements may be entered into the assessment tool,
though they are not necessary for the calculation. To determine
individual fracture risk FRAX\textsuperscript{®} uses ten patient-specific factors,
including age, sex, weight, height, previous fracture occurrence,
tobacco use and femoral neck BMD (as determined by DXA) [29,30].

Studies demonstrate that FRAX\textsuperscript{®} results in high specificity but
low sensitivity in the diagnosis of osteoporosis [22,31]. In other
words, the assessment tool adequately identifies patients without
the disease but fails to identify a portion of patients with the
disease. Therefore FRAX\textsuperscript{®} is best used in conjunction with DXA to
identify patients at risk. While this tool helps persons not at risk to
avoid unnecessary and expensive tests, it may also provide a false
sense of security to those in danger of suffering fragile fractures.
Additionally, the tool may help lower screening costs, but it does
not adequately identify those who require diagnosis and treatment.
A similar tool is the Fracture Risk Calculator developed by Garvan
Institute. The online tool incorporates four clinical risk factors
and BMD for patients 50 years or older. These factors include age,
Bone Turnover Markers

Bone turnover markers (BTMs) may be key to the success of POC bone health diagnostics. There are two categories of BTMs: bone formation markers and bone resorption markers. Bone formation markers are found in serum and plasma, and bone resorption markers are found in serum and urine [43]. While there are numerous BTMs in each category, only a few have been established as accurate correlators to BMD. The accepted bone formation and bone resorption markers are serum PINP (s-PINP) and serum CTX (s-CTX), respectively [44]. Bone formation marker, PINP, is the N-terminal propeptide of type I collagen. It is derived from the post-translational protease cleavage of procollagen molecules [43]. PINP, a monomer or trimer in serum, may be targeted using the automated Roche Elecsys or IDS-iSYS assays. The Roche Elecsys captures both the monomeric and trimeric forms while the IDS-iSYS captures only the trimeric form [45]. These precise assays meet clinical standards because they produce low variability and remain stable at room temperature [44].

Osteocalcin (OC) is a late marker of osteoblast activity. It has been used in research; however, it is unstable, has a short half-life and is also influenced by circadian rhythm [43]. Despite its limitations in research, a negative correlation has been established between non-carboxylated OC and hip fractures in postmenopausal women [46]. Bone resorption marker, s-CTX, is the C-terminal telopeptide of type I collagen. It is produced by the cleavage of type I collagen by the cathepsin K enzyme. CTX exists in two isomerized forms, α and β. Following further isomerization, they are referred to as isomerized forms D and L, respectively [43]. While s-CTX has been established as a suitable marker for measuring bone resorption, the compound is known to be strongly susceptible to circadian variation [47]. It has been detected at maximum levels in the serum during mid-morning (05:00) and at minimum levels in the serum during mid-afternoon (14:00) [48,49]. It is also greatly affected by food intake [43]. For these reasons, experts recommend samples be collected early in the morning after an evening of fasting and measurements be repeated with little environmental variation [50]. Bone resorption marker, urinary NTX (u-NTX), has also demonstrated great promise for use in clinical diagnostics. The marker is measured in urine samples which eliminates the need for medical personnel and laboratory instruments, increases its potential for use in a POC device and reduces patient discomfort and risk of infection. Further, NTX is less susceptible to circadian variations than CTX [43]. The major downside to the use of this BTM is that urine collection over several hours is necessary for testing [51]. BMD measurement using BTMs offers several key advantages. DXA and other imaging modalities give static measurements that cannot reveal a change in bone turnover rate. And a substantial amount of bone must be lost before those who interpret DXA results will categorize patients as high-risk and in need of treatment. On the other hand, BTM quantification requires a small sample volume and can indicate rate of change of bone turnover.

Antibodies

Antibodies (Abs) are key components in the capture and detection of BTMs. Abs are immunoglobulin proteins produced by the immune system in response to pathogens referred to as antigens (Ags). They are both highly specific and bind with high affinity. Specificity is a key characteristic of Abs which makes them ideal in the capture of BTMs. CTX from a human can be injected into a different species, such as a goat or rabbit. The protein will be recognized as a foreign Ag, and an immune response will occur resulting in the production of anti-CTX (α-CTX) Abs. These same Abs (i.e. primary Abs) can then be injected into a different species to develop Abs against those Abs (e.g. anti-α-CTX Abs). These are referred to as secondary Abs. These secondary Abs can then have labels attached to them, such as gold particles or enzymes, making them readily detectible.

Both types of Abs may be utilized in the capture of peptides, proteins or hormones and for the development of appropriate clinical assays. Aptamers are single-stranded nucleic acids that carry the potential to replace Ab in the capture and measurement of BTMs [52,53]. Aptamers demonstrate high specificity and affinity (i.e. tight binding) like their Ab counterparts; however, they may be synthesized in the laboratory removing the need for animals [53]. In addition, aptamers have demonstrated greater stability than Ab, as they are less susceptible to denaturing or losing their structure
which is most suitable for identifying persons not at risk due to ethics and cost, aptamers offer a promising alternative to BTMs. As science works to move away from the use of animals, DXA gives a static measurement. Abs have been used to capture sample volumes, are used to indicate bone remodeling rates, while Microfluidics, small-scale tools that can measure BTMs in small quantitation of BTMs in microfluidics. QUS assessment of bone microarchitecture through QUS and bone turnover rate through for fracture than those at risk. POC technologies assess bone health; however, concepts from the sandwich process. ELISAs are not able to be translated into POC devices for use in osteoporosis diagnosis. Pulse-echo (PE) ultrasound has demonstrated great promise in helping to identify persons at risk of fragility fractures. PE ultrasound is used in the determination of density index (DI) [63], which is highly correlated with the BMD of the femoral neck [64]. PE focuses on the thickness of the cortical bone as it is known to diminish in osteoporotic bone [65,66]. This thickness is used in combination with the age, height and weight of the patient to calculate a DI [64]. While this measurement cannot perfectly identify patients at risk of osteoporosis (roughly 30% of patients require verification with other diagnostics), it represents a significant improvement over calcaneal ultrasound and peripheral DXA. Calcaneal QUS and peripheral DXA result in 56% and 39-56% accuracy, respectively [63]. PE ultrasound does not yet measure up to central DXA; however, its portability may lead to its eventual use in osteoporosis POC devices.

Future of Bone Health Diagnostics

Current standards for bone health diagnostics include DXA which is costly and unavailable to most of the world, as well as FRAX® which is most suitable for identifying persons not at risk for fracture than those at risk. POC technologies assess bone microarchitecture through QUS and bone turnover rate through quantitation of BTMs in microfluidics. QUS assessment of bone microarchitecture estimates bone strength better than DXA. Microfluidics, small-scale tools that can measure BTMs in small sample volumes, are used to indicate bone remodeling rates, while DXA gives a static measurement. Abs have been used to capture BTMs. As science works to move away from the use of animals due to ethics and cost, aptamers offer a promising alternative to Abs. In order to close the osteoporosis care gap, the field should incorporate these advancements in technology.

Point-of-Care

The two most promising technologies for bone health point-of-care (POC) diagnostics are QUS and microfluidics. QUS, while more commonly used to measure the peripheral skeleton when central fractures are most debilitating has been shown to accurately assess bone properties that may be correlated to fracture risk [57-59]. Microfluidic and similar BTM-detection technologies have been developed to rapidly quantify BTMs at lower costs and without the need for large laboratory equipment [60-62].

POC Ultrasound

Several QUS technologies have been developed and tested for use in osteoporosis diagnosis. Pulse-echo (PE) ultrasound has demonstrated great promise in helping to identify persons at risk of fragility fractures. PE ultrasound is used in the determination of density index (DI) [63], which is highly correlated with the BMD of the femoral neck [64]. PE focuses on the thickness of the cortical bone as it is known to diminish in osteoporotic bone [65,66]. This thickness is used in combination with the age, height and weight of the patient to calculate a DI [64]. While this measurement cannot perfectly identify patients at risk of osteoporosis (roughly 30% of patients require verification with other diagnostics), it represents a significant improvement over calcaneal ultrasound and peripheral DXA. Calcaneal QUS and peripheral DXA result in 56% and 39-56% accuracy, respectively [63]. PE ultrasound does not yet measure up to central DXA; however, its portability may lead to its eventual use in osteoporosis POC devices.

Another use of ultrasound technology in bone health assessment is the development of a parameter called the fragility score (FS). A recent study compared this parameter to spinal DXA to determine how well it could identify patients at risk of fragility fractures. The ultrasound scan was performed on the abdomen and the resulting images were processed using a novel algorithm that assigns a FS to the patient to calculate a DI [64]. While this measurement cannot perfectly identify patients at risk of osteoporosis (roughly 30% of patients require verification with other diagnostics), it represents a significant improvement over calcaneal ultrasound and peripheral DXA. Calcaneal QUS and peripheral DXA result in 56% and 39-56% accuracy, respectively [63]. PE ultrasound does not yet measure up to central DXA; however, its portability may lead to its eventual use in osteoporosis POC devices.
Table 1: Ultrasound technologies for bone assessment.

<table>
<thead>
<tr>
<th>Ultrasound Technology</th>
<th>Measurement</th>
<th>Validation</th>
<th>Result</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apparent Integrated Backscatter (AIB)</td>
<td>Femoral head ex vivo</td>
<td>micro-CT</td>
<td>Correlation of ( r = 0.69 ) between AIB and trabecular BV/TV with compensation for sample-probe distance and cortical thickness</td>
<td>[67]</td>
</tr>
<tr>
<td>Broadband Ultrasound Backscatter (BUB)</td>
<td>Distal femur and proximal tibia ex vivo</td>
<td>Bone mechanical properties</td>
<td>Significant correlation of backscatter parameters with ultimate strength of trabecular bone and bone volume fraction (( r = 0.90 ))</td>
<td>[57]</td>
</tr>
<tr>
<td>Fragility Score (FS)</td>
<td>Abdominal scan of lumbar vertebrae in vivo</td>
<td>Spinal DXA</td>
<td>F.S. performed slightly better than DXA at identifying persons at risk of fragility fracture.</td>
<td>[42]</td>
</tr>
<tr>
<td>Frequency Dependent Backscatter Coefficient (BSC)</td>
<td>Bovine proximal femur trabecular bone samples ex vivo</td>
<td>Apparent bone density using a balance and a mass cylinder</td>
<td>Significant correlation between apparent bone density and backscatter coefficient (0.5 MHz: ( r = 0.751 ), 1.0 MHz: ( r = 0.808 ))</td>
<td>[69]</td>
</tr>
<tr>
<td>Integrated Reflection Coefficient (IRC)</td>
<td>Proximal femur, Proximal radius, Proximal and distal tibia in vivo</td>
<td>Axial DXA</td>
<td>Cortical thickness at distal &amp; proximal tibia with patient age and weight gave significant BMD __时刻. Sensitivity: 86%, Specificity: 100%</td>
<td>[64]</td>
</tr>
<tr>
<td>Mean of Backscatter Difference Spectrum (MBD)</td>
<td>Cube-shaped specimens of human cancellous bone ex vivo</td>
<td>Density measurements with digital calipers and electronic scale</td>
<td>Moderate to good correlations between backscatter difference spectrum frequency averaged mean and cancellous density (( r = 0.70-0.95 ))</td>
<td>[58]</td>
</tr>
<tr>
<td>Osteoporosis Score (OS)</td>
<td>Abdominal echographic scanning of lumbar spine in vivo</td>
<td>Spinal DXA</td>
<td>Significant correlations between OS-estimated BMD and DXA BMD (( R^2 ) up to 0.73 and RMS error of 6.3% - 9.3%)</td>
<td>[59]</td>
</tr>
<tr>
<td>Slope of Backscatter Difference Spectrum (SBD)</td>
<td>Cube-shaped specimens of human cancellous bone ex vivo</td>
<td>Density measurements with digital calipers and electronic scale</td>
<td>Weak to moderate correlations between backscatter difference spectrum frequency slope and cancellous density (( r = 0.21-0.80 ))</td>
<td>[58]</td>
</tr>
</tbody>
</table>

Note: \( ^{\text{BV/TV}} \): Bone volume fraction.

**Microfluidic and BTM-Detection Technologies**

Microfluidic technology is used to develop POC devices for the diagnosis of osteoporosis. Microfluidic technologies are highly specific and sensitive, cost effective and easily made portable; they also require small sample volumes. Further the systems can operate without the need for trained medical personnel. Multiplex microfluidics have the ability to detect multiple analytes in a single system. They are a focus in bone health diagnostics as research has found that more than one protein is needed to gain a full understanding of physiologic conditions [43]. Yun et al. [60] developed a label-free electronic biosensor that measures BTMs using electrochemical impedance spectroscopy (EIS). The system can be used for multiplexing without the need for secondary labels. According to the researchers, based on the methodology, a wide array of proteins can be measured by simply incorporating different Abs into the system. They began with the detection of CTX by applying a self-assembled monolayer of dithiodipropionic acid to a gold electrode which served as the working electrode in the system.

Biotinylated Abs specific to CTX were immobilized on the surface using streptavidin as it has a high binding affinity for biotin. EIS responses proved to increase with Ag concentration. The researchers achieved a detection limit of 30 ng/mL and a dynamic range of 3 µg/mL [60] (Table 2). More recently Khashayar et al. [61] published proof-of-concept of a multiplex microfluidic platform for the detection of BTMs. The group used electrochemical sensing to determine BTM concentrations from a serum sample. Gold electrodes were fabricated in a microfluidic chamber and manipulated to immobilize Abs specific to CTX and OC. The system enables capture of the two BTMs and measures oxidative peaks that can then be converted to concentrations. This method measures current response which has been shown to correlate linearly with the logarithmic concentration of the BTM. The group achieved limits of detection of 1.39 pg/mL and 1.94 ng/mL for CTX and OC, respectively [61] (Table 2).

Based on technology of the sandwich ELISA, Lee et al. [62] developed a lateral flow immunosassay (LFA) for the detection of s-CTX and u-NTX. BTMs were captured using Abs without the use of electronic biosensors. LFA strips were fabricated by combining a treated sample pad, a conjugate pad with dried and labeled Abs, a nitrocellulose analytical membrane, a wicking pad to collect
excess fluids, and a backing material for the entire strip (Figure 1). Anti-CTX and anti-NTX Abs were immobilized on the analytical membrane and secondary Abs for each were immobilized further down the strip (i.e. test and control line). Sample containing Ag was applied to the sample pad which then wicked to the conjugate pad. This remobilized Abs specific to the Ag of interest that were conjugated to colloidal gold and had been previously dried onto the conjugate membrane. All contents then wicked to the analytical membrane. The present Ag was sandwiched between the Abs from the conjugate pad and those present on the analytical membrane.

The gold-Ab conjugate bound to Ag present in the sample produced a color signal at the test and control lines that could be correlated to Ag concentration. The researchers used a digital camera and ImageJ software to quantify the results. The findings were compared to commercial NTX and CTX ELISAs and demonstrated a correlation of 0.913 and 0.872, respectively [62] (Table 2) (Figure 1). Microfluidic technologies offer great potential for the development of POC devices for bone health assessment. These devices are more cost effective than DXA and allow for the detection of multiple BTMs within small sample volumes. The scale, cost and simplicity of these technologies means their commercialization could reach far more osteoporotic patients at risk of fragility fracture than any other bone diagnostic tool available. To our knowledge, none of these devices have been commercialized but published findings demonstrate the field is moving in the right direction.

Table 2: Microfluidic technologies for quantifying bone turnover markers.

<table>
<thead>
<tr>
<th>Microfluidic Technology</th>
<th>BTM(s)</th>
<th>Validation</th>
<th>Results</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Label-Free Electronic Biosensor using Electrochemical Impedance Spectroscopy</td>
<td>CTX</td>
<td>Ag/AgCl reference electrode</td>
<td>Limit of Detection: 50 ng/mL Dynamic Range: up to 3 μg/mL</td>
<td>[60]</td>
</tr>
<tr>
<td>Multiplex Microfluidic Platform with Electrochemical Sensing</td>
<td>s-CTX; Osteocalcin</td>
<td>ECLIA</td>
<td>Limits of Detection: s-CTX: 1.39 pg/mL Osteocalcin: 1.94 ng/mL Dynamic Range: s-CTX: 25–1008 pg/ML Osteocalcin: 9–42 ng/ML</td>
<td>[61]</td>
</tr>
<tr>
<td>Lateral Flow Immunoassay</td>
<td>s-CTX; u-NTX</td>
<td>ELISA</td>
<td>Correlation of LFA to ELISA: s-CTX: 0.872 u-NTX: 0.913 Precision of LFA to ELISA: s-CTX: 0.995 u-NTX: 0.974</td>
<td>[62]</td>
</tr>
</tbody>
</table>

Note: *ECLIA: Electrochemiluminescence immunoassay.

Figure 1: Basic lateral flow (LFA) assembly. The LFA assembly consists of a treated sample pad, conjugate pad, analytical nitrocellulose membrane and an absorbent pad. The materials overlap to allow fluid to wick through the device. Proteins specific to the target analyte are present on the conjugate pad and at the test and control lines.

Discussion

Osteoporosis characterized by low BMD and increased risk of fragility fracture affects hundreds of millions of individuals worldwide most of whom have not been diagnosed. The WHO established DXA and nation specific FRAX® as standards for osteoporosis diagnosis and fracture risk assessment. These tools, while the best available are insufficient. DXA scans are expensive and subject to variation and they require operation by skilled technicians. Additionally, the technology is not suitable for translation into POC systems. FRAX®, while more attainable is best suited for identifying persons not at risk of fracture. Ultrasound and microfluidic technologies can determine bone properties and remodeling rates, respectively. However, automated ultrasound systems and assessment protocols must be developed to overcome variability in measurements. Microfluidic systems must be adapted to be multiplex and give results that can be interpreted easily and cheaply. While there is currently no cure for osteoporosis there are several measures that can be taken to delay its progression and reduce risk of fracture.

Parents of adolescents who are aware of osteoporosis within their genealogy can help their children take known preventative measures to enhance PBM accumulation. For example, children should consume diets high in calcium, receive adequate doses of vitamin D [4] and take part in physical activities that include impact- and muscle-loading [70]. Furthermore, parents can warn children that tobacco use [6,71,72] and inadequate nutrition [73] can prove damaging to the skeleton in the long term. Similar preventative measures should be taken by adults who have surpassed the age at which bone mass peaks. Adults should also ensure adequate calcium intake and vitamin D exposure [74,75] and avoid tobacco.
use [4,71]. Osteoporotic patients may be treated with bisphosphonates to inhibit bone resorption and maintain bone mass [1]. Other treatments exist and may be more appropriate for certain patients; however, osteoporosis is most commonly treated with bisphosphonates [75]. Preventative measures and therapy are critical for those at risk of osteoporotic fracture; however, diagnosis remains a global challenge on which research efforts should be focused.

Conclusion

Osteoporosis debilitates hundreds of millions of people across the globe. There should be an emphasis during childhood education on lifestyle choices that can prevent onset of the disease. In addition, diagnosis and treatment need to be improved. For example, standardized protocols and automation are needed to enhance QUS. A better understanding needs to be developed for the interpretation of BTM measurements. To that end, a microfluidic POC device capable of quantifying BTMs and novel QUS technology that can accurately establish bone properties carry great promise.

Acknowledgement

M Crow was monetarily compensated for contributions to this manuscript. This work was supported by the National Science Foundation (ESBS 1700299). This work is posthumously dedicated to Dr James Holda (1954-2019).

Conflict of Interest

Marnie Saunders, Sharon Truesdell, Estee George, James Holda and Christopher Van Vranken declare that they have no conflict of interest.

References


ISSN: 2574-1241
DOI: 10.26717/BJSTR.2019.23.003838


This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: https://biomedres.us/submit-manuscript.php

Assets of Publishing with us
- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

https://biomedres.us/